Stefanetti G, MacLennan C, Micoli F
Molecules. 2022; 27(19).
PMID: 36234967
PMC: 9572008.
DOI: 10.3390/molecules27196432.
Kim D, Hong J, Choi Y, Han J, Kim S, Jo G
J Microbiol Biotechnol. 2020; 30(11):1760-1768.
PMID: 32876069
PMC: 9728160.
DOI: 10.4014/jmb.2005.05046.
Baranova D, Willsey G, Levinson K, Smith C, Wade J, Mantis N
Pathog Dis. 2020; 78(4).
PMID: 32589220
PMC: 7371154.
DOI: 10.1093/femspd/ftaa029.
Dworaczek K, Kurzylewska M, Karas M, Janczarek M, Pekala-Safinska A, Turska-Szewczuk A
Mar Drugs. 2019; 17(5).
PMID: 31035397
PMC: 6562859.
DOI: 10.3390/md17050254.
Zamorano-Sanchez D, Xian W, Lee C, Salinas M, Thongsomboon W, Cegelski L
mBio. 2019; 10(2).
PMID: 31015332
PMC: 6479008.
DOI: 10.1128/mBio.00670-19.
Brucellosis: Improved Diagnostics and Vaccine Insights from Synthetic Glycans.
Bundle D, McGiven J
Acc Chem Res. 2017; 50(12):2958-2967.
PMID: 29219305
PMC: 5738633.
DOI: 10.1021/acs.accounts.7b00445.
Conjugate Vaccines from Bacterial Antigens by Squaric Acid Chemistry: A Closer Look.
Xu P, Kelly M, Vann W, Qadri F, Ryan E, Kovac P
Chembiochem. 2017; 18(8):799-815.
PMID: 28182850
PMC: 5664186.
DOI: 10.1002/cbic.201600699.
A monoclonal antibody that targets the conserved core/lipid A region of lipopolysaccharide affects motility and reduces intestinal colonization of both classical and El Tor Vibrio cholerae biotypes.
Levinson K, Baranova D, Mantis N
Vaccine. 2016; 34(48):5833-5836.
PMID: 27773473
PMC: 5193159.
DOI: 10.1016/j.vaccine.2016.10.023.
Development of a bead-based Luminex assay using lipopolysaccharide specific monoclonal antibodies to detect biological threats from Brucella species.
Silbereisen A, Tamborrini M, Wittwer M, Schurch N, Pluschke G
BMC Microbiol. 2015; 15:198.
PMID: 26438077
PMC: 4595103.
DOI: 10.1186/s12866-015-0534-1.
Immunochemical characterization of synthetic hexa-, octa- and decasaccharide conjugate vaccines for Vibrio cholerae O:1 serotype Ogawa with emphasis on antigenic density and chain length.
Ftacek P, Nelson V, Szu S
Glycoconj J. 2013; 30(9):871-80.
PMID: 23955520
PMC: 3839634.
DOI: 10.1007/s10719-013-9491-9.
Phase variable O antigen biosynthetic genes control expression of the major protective antigen and bacteriophage receptor in Vibrio cholerae O1.
Seed K, Faruque S, Mekalanos J, Calderwood S, Qadri F, Camilli A
PLoS Pathog. 2012; 8(9):e1002917.
PMID: 23028317
PMC: 3441752.
DOI: 10.1371/journal.ppat.1002917.
Oxidative depolymerization of polysaccharides by reactive oxygen/nitrogen species.
Duan J, Kasper D
Glycobiology. 2010; 21(4):401-9.
PMID: 21030538
PMC: 3055593.
DOI: 10.1093/glycob/cwq171.
Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera.
Schild S, Nelson E, Bishop A, Camilli A
Infect Immun. 2008; 77(1):472-84.
PMID: 19001078
PMC: 2612262.
DOI: 10.1128/IAI.01139-08.
Investigation towards bivalent chemically defined glycoconjugate immunogens prepared from acid-detoxified lipopolysaccharide of Vibrio cholerae O1, serotype Inaba.
Grandjean C, Boutonnier A, Dassy B, Fournier J, Mulard L
Glycoconj J. 2008; 26(1):41-55.
PMID: 18648931
DOI: 10.1007/s10719-008-9160-6.
Microbial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII pathway.
Duan J, Avci F, Kasper D
Proc Natl Acad Sci U S A. 2008; 105(13):5183-8.
PMID: 18381820
PMC: 2278222.
DOI: 10.1073/pnas.0800974105.
Flagellin glycans from two pathovars of Pseudomonas syringae contain rhamnose in D and L configurations in different ratios and modified 4-amino-4,6-dideoxyglucose.
Takeuchi K, Ono H, Yoshida M, Ishii T, Katoh E, Taguchi F
J Bacteriol. 2007; 189(19):6945-56.
PMID: 17644592
PMC: 2045217.
DOI: 10.1128/JB.00500-07.
Positive electrospray ion trap multistage mass spectrometric fragmentation of synthetic analogs of saccharide part of lipopolysaccharides of Vibrio cholerae O:1.
Kovacik V, Bekesova S, Tvaroska I, Kovac P
J Am Soc Mass Spectrom. 2006; 17(6):749-756.
PMID: 16600622
DOI: 10.1016/j.jasms.2006.02.006.
Synthetic fragments of Vibrio cholerae O1 Inaba O-specific polysaccharide bound to a protein carrier are immunogenic in mice but do not induce protective antibodies.
Meeks M, Saksena R, Ma X, Wade T, Taylor R, Kovac P
Infect Immun. 2004; 72(7):4090-101.
PMID: 15213154
PMC: 427411.
DOI: 10.1128/IAI.72.7.4090-4101.2004.
Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid.
Boutonnier A, Villeneuve S, Nato F, Dassy B, Fournier J
Infect Immun. 2001; 69(5):3488-93.
PMID: 11292781
PMC: 98317.
DOI: 10.1128/IAI.69.5.3488-3493.2001.
Characterization of Vibrio cholerae O1 El tor galU and galE mutants: influence on lipopolysaccharide structure, colonization, and biofilm formation.
Nesper J, Lauriano C, Klose K, Kapfhammer D, Kraiss A, Reidl J
Infect Immun. 2000; 69(1):435-45.
PMID: 11119535
PMC: 97901.
DOI: 10.1128/IAI.69.1.435-445.2001.